Abstract: Drug discovery is a complex process that includes the identification of biological targets as well as the identification of leads that aim at altering or inhibiting the function of a particular target. The budding yeast Saccharomyces cerevisiae has long been recognized as a valuable model organism for studies of eukaryotic cells since many of the basic cellular processes between yeast and humans are highly conserved. In this review, we highlight emerging yeast-based functional genomic and proteomic technologies that are advancing the utility of yeast as a model organism in the drug-discovery process. These approaches include the utilization of yeast deletion strain collection, synthetic genetic array combined with chemical genomics, variations of the yeast two-hybrid system, yeast biosensor assay, and protein microarrays. Although still at an early stage, these technologies show promise as novel and useful methods for development of target-specific therapeutic approaches.
INTRODUCTION
Drug discovery is a lengthy and costly process which involves target identification and validation, drug screening and safety assays, development of animal models and ultimately, testing of potential drug candidates in clinical trials. The development of a novel drug may take 10-15 years, with cost estimates of ~800 million US$ (DiMasi et al., 2003) . Any technology that is able to increase the speed of the screening process and deliver more reliable predictions on the efficacy or potential toxicity of drug candidates, and thereby effectively help to cut cost and time in this process, would be helpful. Both genomics and proteomics have been considered to be effective for such purpose. Whereas genomics can speed up the target identification process by making complete genome sequences of a wide range of organisms available (http://www.genomenews network.org/resources/sequenced _ genomes / genome _ guide _ p1.shtml), proteomics holds the promise of identifying the complete set of proteins expressed in a particular cell at a given stage, as well as uncovering the myriad of regulatory networks that are created by protein-protein interactions. Ultimately, using systems biology one should be able to receive a "snap-shot" of a cell with all information regarding expressed proteins, their particular localization within the cell, their post-translational modification status and their interactions with various other proteins expressed at the same time.
To date, the major impact of proteomics has been on processes in the early stages of drug development, namely target identification and validation. In particular, the use of *Address correspondence to this author at the Institute of Veterinary Biochemistry and Molecular Biology, University of Zurich-Irchel, Winterthurerstrasse, 190, Switzerland; Email: stagljar@vetbio.unizh.ch model organisms such as the bakers yeast Saccharomyces cerevisiae, the fruit fly Drosophila melanogaster and the worm Caenorhabditis elegans has been very helpful since many human genes have orthologues in lower eukaryotes (consortium, 2001; Venter et al., 2001) . In this review, we focus on the use of the model organism S. cerevisiae and its applications in finding and characterizing disease pathways, as well as on attempts at converting yeast to an in vivo screening platform to identify novel compounds in the early stage of drug development. These include the use of engineered yeast strains in assessing the toxicity of drug candidates, synthetic genetic array combined with chemical genomics, the establishment of large scale protein interactions maps from several organisms and attempts to use these maps to predict pathways implicated with human diseases, the direct use of yeast two-hybrid strategies to identify novel drug candidates that alter or inhibit protein-protein interactions, and the application of protein microarrays for drug discovery. The reader is referred to several excellent recent reviews covering additional yeast based functional genomics technologies that are not covered here (Hughes, 2002; Melese and Hieter, 2002; Parsons et al., 2004; Tucker, 2002) .
YEAST AS A MODEL SYSTEM FOR DRUG DISCOVERY
The unicellular eukaryote S. cerevisiae is an excellent model system for drug discovery: it is inexpensive to maintain and grow, it is classified as a GRAS (generally recognized as safe) microorganism, its entire genome has been sequenced (Goffeau et al., 1996) , its ~ 6, 200 open reading frames (ORFs) exist in a readily usable form (Hudson et al., 1997) , it is well suited for the expression of heterologous proteins, and it contains a multitude of selective markers, including markers for nutritional selection (e.g. HIS3, URA3) , drug resistance (e.g. kanMX, patMX, natMX) and drug susceptibility (e.g. URA3, cyhR). Thus, its experimental tractability, combined with the remarkable conservation of gene function throughout evolution, makes yeast an ideal genetic organism. As a model of fundamental cellular processes and metabolic pathways of the human, yeast has improved our understanding and facilitated the molecular analysis of many disease genes (reviewed in Snyder and Kumar, 2002) .
USING THE YEAST DELETION STRAIN COLLEC-TION FOR DRUG SCREENING
In model organisms, a classic way to assess gene function and to dissect protein interaction networks involves deleting genes of interest and then studying the phenotypic consequences of the deletion. For the yeast S. cerevisiae, studies on genome wide loss of function have been possible due to the creation of a collection of yeast deletion strains. The gene deletion collection, created by the Saccharomyces Genome Deletion Project consortium (http://sequencewww.stanford.edu/group/yeast_deletion_project/), represents an array of ~ 4, 700 individual haploid yeast strains which have a single non-essential ORF deleted. A second collection consists of an array of heterozygous-diploid strains deleted in either essential or non-essential genes (Giaver et al., 1999) .
The collections of haploid and heterozygous yeast strains enable high-throughput phenotypic analyses of yeast mutants. Such cell-based assays offer two main advantages for drug target screening compared to traditional biochemical approaches that involve purification of the target protein.
First, in cell-based assays a protein target is localized in the cellular milieu, thus favoring its native conformation and association with its normal interacting partners. Second, yeast cell-based assays are selected for chemical compounds which are able to pass through the yeast cell envelope and are not inactivated or exported from the cell. Thus, a drug target and chemical compounds that are identified through cell-based assays have passed important validation steps. Such information provides a head start compared to many in vitro assays and can save valuable time and costs in the development of the drug.
Two interesting studies illustrated potential applications for the yeast haploid deletion mutant collection. In a chemical genomics screen, Zewail et al., (2003) identified genes exhibiting altered sensitivity to wortmaninn, a clinical immunosuppressive and anti-inflammatory agent. The authors first tested 4, 850 haploid deletion strains and 1, 175 heterozygous diploid deletion strains for hypersensitivity or resistance to wortmaninn. The initial screen generated a global view which implicated 1, 067 genes in the wortmannin responsive network. In particular, the study revealed novel complex connections between the phosphatidylinositol metabolic pathways and several biological processes including DNA replication and the DNA damage induced checkpoint response. In another approach, Tucker and Fields (2004) quantified the sensitivity of the yeast deletion strains to hydrogen peroxide, menadione, ibuprofen and mefloquine. The screens revealed 659 strains that are sensitive to at least one chemical. An interesting comparison of these results with previous other large-scale studies determined new pathways modulated by the chemicals examined. For example, correlation of the data obtained with the hydrogen peroxide and informations from large-scale two-hybrid screens determined YBR216C as a novel component of the oxidative stress response.
Drug Induced Haploinsufficiency Assay
In vitro experiments performed to characterize the binding of a drug to a target protein are limited in that they are unable to take into consideration the potentially complex network of interactions occurring within a cell between a drug and its potential target or targets. The use of heterozygous diploid yeast deletion strains to monitor the in vivo activity of a given compound can overcome this problem. Such studies are based on two general principles. First, heterozygous strains show enhanced sensitivity to growth inhibitory chemicals when compared to the corresponding wild type strains due to the decrease in gene dosage of a drug target from two copies to one. This phenomenon is known as drug induced haploinsufficiency (Fig. 1A) . Second, the cellular consequences of genetic or pharmacological inhibition of a particular ORF are phenotypically similar; therefore, both a gene deletion and inhibition of a gene product via chemical means are functionally equivalent (Marton et al., 1998) .
Recently, Baetz et al., (2004) analysed the mode of action of the angiogenesis and metastasis inhibitor dihydromotuporamine C. A compound-induced haploinsufficiency screen using the yeast heterozygous deletion diploid set uncovered putative pathways and/or targets affected by the preclinical molecule. Correlation between the drug mode of action in yeast and in humans revealed that dihydromotuporamine C targets sphingolipid metabolism.
In order to discover primary drug targets of some commonly used medical compounds, Giaver et al. (1999) exposed a pool of 233 heterozygous mutants to a sub-lethal compound concentration (Fig. 1B) . After a few generations of growth, only yeast heterozygote for the drug target genes should show a fitness impairment (hypersensitivity phenotype). To quantify the amount of each strain and to estimate the abundance of each individual mutant within the rest of the population (relative abundance), the following approach was used.
During the construction of the gene deletion collection, a unique 20-bp barcode sequence was inserted in the place of the deleted gene within each heterozygous yeast strain. For the experiment, a pool of heterozygous diploids was exposed to drug treatment and at different time points after drug treatment, total genomic DNA was isolated. From the genomic DNA, the region covering the unique 20-bp barcodes was PCR amplified and used to probe an oligonucleotide chip carrying the complement of each molecular tag. Thus, if certain haploids are unaffected by the drug treatment, the haploids will grow normally, have their barcodes amplified and thus the product will hybridize to the oligonucleotide chip. However, if certain yeast haploids are sensitive to the drug, their particular barcode will not be represented in the PCR amplification product (Fig. 1B) .
For example, ALG7, a gene involved in glycolsylation, is inhibited by tunicamycin. At a concentration of 0.5 micro gram / ml of the drug, the authors noticed a difference of growth between the alg7/ALG7 and the wild type cells. Including the yeast strain alg7/ALG7 as a tunicamycin induced haploinsufficient control, 232 other strains could be tested for their sensitivity to the compound. To accomplish this, the pool of 233 strains were grown for 15 generations in the presence or absence of the drug. Specific hybridizations of the barcode PCR products on an oligonucleotide array showed a significant decrease in abundance of 3 particular strains from the pool upon drug treatment. Therefore, the corresponding deleted gene products resulted in strains which are sensitive to tunicamycin. The abundance of the remaining yeast strains stayed approximately equal. Via this approach, the authors identified ALG7 (control) and two other genes, YMR007w and YMR266w, as possible drug targets or genes involved in drug availability for tunicamycin.
Very recently, this approach has been successfully scaled up and used to identify drug targets at the genome-wide scale. By testing 10 diverse compounds on the complete pool of ~6, 000 heterozygous deletion strains, Giaver et al., (2004) found sensitivity of similar strains to three apparently distinct therapeutical compounds. Identical haploinsufficiency profiles prompted the authors to focus on the chemical structure of the compound. Interestingly, the analysis revealed that dyclonine, fenpropimorph and alverine citrate shared the same chemical core structure. Hence, the method not only identifies genes whose products are known to interact directly with the tested compounds but can also help to discover new structure-activity relationships.
The major drawback of this approach is the inability to identify compounds interacting with non-protein elements in the cell, such a DNA or ergosterol. Moreover, due to the redundancy of protein activities, the drug effect could be masked. In these particular cases, the use of the haploid strain collection would be more informative.
SYNTHETIC GENETIC ARRAY (SGA) ANALYSIS AS A MEANS TO IDENTIFY CHEMICAL INTERAC-TIONS
Since ~73% of the 6, 200 predicted ORFs are nonessential, it appears that yeast have evolved mechanisms to buffer or compensate for genetic variations caused by certain gene deletions. A fundamental mechanism exploited by the cell to tolerate such deletions is redundancy (Hartman et al., 2001) . Because of the high number of redundant genes in yeast, the functions of thousands of genes remain to be elucidated. To uncover such redundant functions, Tong et al., (2001 Tong et al., ( , 2004 developed an automated synthetic lethality analysis employing the ~4, 700 nonessential genes in S. cerevisiae. These screens, based on loss of function, also help to establish a comprehensive protein interaction network. Basically, a query mutation is introduced in a haploid strain MATα. By an automated procedure, this mutant strain is individually crossed with an array of MATa strains each carrying a deletion in a non-essential gene. After inducing sporulation of the heterozygous diploids, haploid meiotic spore progeny are transferred to selective media to isolate haploids mutated for both the query mutation and the non-essential gene. The double-mutant haploid strains are then monitored for growth defects in order to analyze the synthetic lethality relationships between the two genes. Two nonessential genes are regarded as synthetic lethal if their simultaneous deletion impairs growth. This suggests that the two genes act in a single biochemical pathway or in related pathways ( Fig. 2A) . This approach has been used to test 132 different query genes and from these experiments a genetic interaction network of ~1, 000 genes and ~4, 000 interactions has been created.
Recently, Parsons et al., (2004) combined results of chemical-genetic and synthetic lethal genetic interactions to dissect target pathways and to discover the targets of several growth-inhibitory compounds. As shown in Fig. 2B , a nonessential gene A can cooperate with the activities of gene B to provide drug inhibition. If a gene A deletion is combined with a drug inhibiting gene B function, a cell hypersensitivity phenotype characteristic of a chemical-genetic interaction is produced. Moreover, deleting gene A and B, or a gene A deletion coupled with drug inhibition of the product of gene B, should result in identical biological effects, i.e. a yeast growth defect. In other words, the synthetic lethal genetic interaction profile for gene A and a drug target gene B should mimic the chemical-genetic interaction profile for these two genes (compare Figs. 2A and 2B) . By systematically testing the sensitivity of the ~4, 700 viable yeast deletion set (gene A) to 12 diverse inhibitory compounds targeted against characterized gene products (gene B), the authors could establish a chemical-genetic interaction profile for each compound. Profile analysis showed that deletion of genes involved in multidrug-resistance, like genes for ergosterol biosynthesis or the vacuolar H + -ATPase, give a hypersensitive phenotype in the presence of the drugs. A rational exclusion of the multidrug-resistance genes revealed more reliable compound-specific profiles. Finally, the authors tried to correlate results from the chemical-genetic profiles of the 6 better characterized chemical compounds with the synthetic lethal genetic interaction profiles of 57 genes known to be involved in pathways related to the 6 compounds. From their comparison, Parsons et al., (2004) reconfirmed already known drug targets for the six compounds and more interestingly managed to assign roles to uncharacterised genes, for example a putative role for Vid21 in chromatin remodeling after DNA damage.
Based on this approach, a few attractive perspectives emerge. For instance, human genes could be used to replace their yeast counterparts and the human target proteins could be screened to evaluate them as the primary target, the side effect of drugs on those targets as well as biochemical pathways involved in the metabolism of known or new therapeutic agents. Another use would be to characterise drug targets and pathways during multi-component therapeutics (Borisy et al., 2003) .
YEAST BIOSENSOR ASSAYS AND DRUG SCREEN-ING
Biosensors are analytical systems combining a biological sensing part which specifically recognizes a given chemical or physical change, and a signal transduction part that is able to transduce the environmental changes to an easily detectable signal. Ideally, convenient molecular biosensors would be reagentless, easy to synthesize and simple to modify in order to modulate their specific binding properties.
Recently, Tucker and Fields (2001) developed a system to generate generic biosensors in vivo. In their study, they used S. cerevisiae as a detector organism for the macrolide FK506 and the human hormone estrogen. The authors adapted the enzyme dihydrofolate reductase (DHFR) to monitor for cell survival. This protein plays a central role in carbon metabolism and is required for yeast survival. Furthermore, the original yeast gene can be replaced by its murine analogue without growth perturbation. In the study, the N-terminal part of the murine DHFR (mDHFR) protein is bridged by either the human receptor for macrolides FK506 (FKP12) or to the estrogen receptor-α (ERα) ligand binding domain (Fig. 3) to the remaining C-terminal part of mDHFR. The bridge includes a 10 amino acid linker to serve as a hinge. Furthermore, the corresponding chimeric protein needs to be unstable or temperature-sensitive in the absence of the ligand in order to detect variation in yeast growth upon addition of ligand. Yeast expressing ERα bridging mDHFR display a temperature-sensitive phenotype at 38.5°C. To obtain a similar result with FKP12, the mDHFR was mutated at position 66 (P66L). That way, at 38.5°C, yeast with the mDHFR-ERα or mDHFR-FKP12 proteins are not viable because of mDHFR stability or activity perturbation. In the presence of the proper ligand (FK506 or estrogen), yeast growth can be restored in a dose-dependent manner. To validate the system, a chemical screening was performed with 20 estrogen analogs and other hormones or compounds to test their binding specificity to the mDHFR-ERα chimeric protein. As demonstrated in a growth assay, this biosensor was able to distinguish its specific ligand, estrogen. The authors give three possible reasons for the reduced growth capabilities supported by the chimeric mDHFR. First, receptor insertion could destabilize the chimeric protein and lead to its degradation. Second, it could change its conformation and decrease mDHFR enzymatic activity. Third, some unknown cofactors could interact with the receptor segment and interfere with its activity and/or stabilization. In all three cases, binding of the ligand to the receptor segment would restore the stability and/or activity of the chimeric protein.
The yeast biosensor approach represents an interesting system for the identification of compounds that interact with a given receptor. One disadvantage of the method is the size of the receptor that can be inserted in mDHFR. In case where the receptor is too large, an alternative could be to work with a particular domain of the receptor.
THE YEAST TWO-HYBRID SYSTEM IN DRUG DISCOVERY
The yeast two-hybrid system was originally developed by Fields and Song (1989) as a genetic assay in yeast to identify and characterize protein-protein interactions. Two interacting proteins reconstitute an artificial transcription factor which in turn activates transcription of an auxotrophic reporter gene such as HIS3 or ADE2. Consequently, those cells expressing two interacting proteins are able to grow on selective medium lacking either histidine or adenine (Fig. 4) . Compared to traditional biochemical methods, its major advantages are its ease of use, speed and the fact that novel protein-protein interactions can be identified through screening of cDNA libraries. In fact, the yeast two-hybrid system has become so popular that more than 4,000 articles describing its use can be found in Medline today.
With regard to screening for novel drugs, the yeast twohybrid system can be broadly applied to two areas: (1) identification of target and its validation and (2) screening for compounds that inhibit the interaction between two therapeutic target proteins.
Use of the Yeast Two-Hybrid System in Target Identification
As a genetic assay, the yeast two-hybrid system is perfectly suitable for high-throughput studies. This has been used successfully to create so-called "whole genome interaction networks" where all proteins of a given organism are systematically tested against each other using high-throughput yeast two-hybrid strategies (reviewed in (Auerbach et al., 2002 . As many proteins that play important roles in human disease have orthologues in lower eukaryotes such as yeast, D. melanogaster or C. elegans, a potential route towards identification of novel targets is to create interactions networks in these model organisms and then try to transfer the insights gained to the human situation. Comprehensive protein interaction maps have been created for yeast (Ito et al., 2001; Uetz et al., 2000) and recently also for D. melanogaster (Giot et al., 2003) and C. elegans . As an example, the D. melanogaster interaction map identified a total of 4, 780 high-confidence interactions, involving 4, 679 proteins. The authors then used the Homophila database which lists all proteins in D. melanogaster that have orthologues implicated in disease pathways in human (Reiter et al., 2001) in order to integrate their protein interaction data with already known disease pathways in human. As an example of this approach, they demonstrate that a previously known transcription factor involved in human B cell non-Hodgkin's lymphoma is connected to two calcium-dependent phosphatases, a finding that suggests calcineurin phosphatases may be valid drug targets for treating lymphomas and other cancer types.
An additional advantage of studying disease relevant protein interactions in model organisms is that phenotypic assays can be carried out very quickly, for example by using RNAi knockdown technology, which is well established in both D. melanogaster and C. elegans (Dykxhoorn et al., 2003) . Using a combination of different target validation technologies, it may eventually become possible to select human proteins involved in a particular disease pathway, identify their corresponding orthologues in D. melanogaster or C. elegans and then carry out yeast two-hybrid screens to identify novel members involved in this pathway. Novel targets are then validated directly in the model organism using synthetic lethality screens and RNAi knockdown strategies, and subsequently used for drug screening. The feasibility of this approach has recently been demonstrated by Vidal and coworkers (1996) . Using several high-throughput yeast two-hybrid screens, they first identified novel proteins involved in TGF-ß signaling in C. elegans and then Fig. (1) . A. Drug-induced haploinsufficiency. Yeast cells with one copy of a drug target gene require less drug (red) to inhibit its target (blue) than the wild-type yeast containing the two copies. Therefore, the heterozygous diploid will become hypersensitive to the presence of a sub-lethal drug concentration B. Haploinsufficiency profiling. A heterozygous yeast strain collection was created by inserting a 20-bp barcode sequence in place of the mutated gene. Each deletion is identified by one unique tag. After drug addition, only the mutants for the drug target gene will display hypersensitivity (yeast with blue tag). Following competitive growth and genomic DNA isolation, tagged regions are PCR amplified. Relative heterozygotes abundances before and after drug treatment are estimated by hybridization of the PCR products on an oligonucleotide array. Yeasts carrying a single copy of the drug target gene (here with blue tag) will not grow in the presence of the drug and will thus be detected only when the drug is absent (control). proceeded to testing the functional relevance of the novel interactions by RNAi analysis (Tewari et al., 2004) . They identified nine TGF-beta signaling modifiers, seven of which are also found in humans.
Identification of Peptide Aptamers Using the Yeast Two Hybrid System
As the major strength of the yeast two-hybrid system is its ability to detect novel protein-protein interactions by screening large collections of protein fragments, an obvious adaptation was the use of random peptide libraries to select peptides which interact with a protein of interest. Brent and colleagues (Colas et al., 1996) first demonstrated the use of so-called peptide aptamer screening by isolating peptides that selectively bound to the cyclin-dependent kinase 2 (Cdk2). A combinatorial library of constrained 20-residue peptides displayed by the active-site loop of E. coli thioredoxin was used to isolate aptamers with affinity to human Cdk2. Isolated aptamers recognized different Cdk2 epitopes with affinities in the nanomolar range and were shown to inhibit Cdk2 activity.
The general strategy of peptide aptamer screening is shown in Fig. 5A . A protein of interest is used as a bait by fusing it to a DNA binding domain. Next, a library of random peptide fragments is constructed. Since peptides are very flexible and usually do not display a defined structure on their own, they are constrained by inserting them into defined positions within a protein scaffold. This technique derives from phage display, where the sequences encoding epitopes are normally placed in a loop structure in the phage surface protein (Benhar, 2001; Wang and Yu, 2004) . Placing the peptide within a loop of the scaffold protein ensures that the peptide is optimally displayed to the bait and also leads to spatial constraints which force the peptide into a limited number of conformations (Fig. 5A) . Scaffold proteins include the Escherichia coli protein thioredoxin (Colas et al., 1996) and GFP (Abedi et al., 1998) . Similar to a conventional yeast two-hybrid screen, the bait is introduced into yeast, together with the peptide aptamer library and aptamers with affinity for the bait are selected (Fig. 5B) . In a further step, peptide aptamers isolated in the first round of screening can be subjected to targeted random mutations and are then reintroduced into yeast to select for optimized aptamers displaying a higher affinity for the original bait. For instance, aptamer variants with increased affinities for Cdk2 were created by mutagenesis of the original aptamers and selection by a yeast two-hybrid strategy (Colas et al., 2000) . Other examples where peptide aptamer screening has been used to great success include the retinoblastoma protein (Yang et al., 1995) and p53 (Oliner et al., 1993) .
Although peptide aptamers have little application as drugs, due to issues such as manufacturing cost, cell permeability and unfavorable ADME (absorption, distribution, metabolism and excretion) properties, they nevertheless represent a great starting point to identify and characeterize protein-protein interaction interfaces that may be later used in screening for inhibitory small molecules. The interaction between the tumor suppressor p53 and the ubiquitin ligase Mdm2, which will be discussed in detail below, represents such an example: yeast two-hybrid assays with p53 and Mdm2 were initially used to pinpoint the p53-Mdm2 binding interface (Freedman et al., 1997) . This strategy also suggests that it may be useful to test inhibition strategies aimed at protein-protein interactions in peptide aptamer screens before embarking on costly small molecule screening projects.
Identification of Small Molecules that Inhibit a ProteinProtein Interaction
There are many compounds that can be used to block protein-protein interactions, including other proteins such as antibodies or single chain antibody fragments, peptides, RNA aptamers, or low molecular weight compounds (small molecules). In practice, owing to factors such as manufacturing costs, tissue distribution, stability or cellular permeability, only small molecules currently represent such useful drugs. And even with small molecules, the scope of application is rather limited: the majority of drugs marketed Fig. (4) . The yeast two-hybrid system. The yeast two-hybrid system is a genetic assay, where the interaction between two fusion proteins, which are co-expressed in yeast, is measured by the transcriptional activation of reporter genes. (A) The bait is a protein of interest "X" fused to the DNA-binding domain of a transcription factor (DBD). The prey is a protein "Y" fused to the activation domain of a transcription factor (AD). If DBD-X and AD-Y interact upon co-expression in yeast, they will form an active transcription factor which is bound to operator sites located upstream of several distinct reporter genes. This "hybrid" transcription factor activates transcription of the downstream reporter genes. Auxotrophic reporter genes such as HIS3 or ADE2 allow growth on selective medium, whereas expression of the reporter gene lacZ is detected using a colorimetric assay. today target either cell surface receptors or enzymes, such as kinases or proteases. A common property of these small molecules is that they bind into well-defined crevices within the target proteins, thereby either stimulating receptor signaling or blocking an enzymatic function. Protein-protein interfaces, on the other hand, are much larger and usually have flat topologies involving many interacting residues spread over a large area.
Although it may not be easy to identify small molecules that effectively bind a large protein-protein interaction interface and disrupt the interaction, it has been suggested that such molecules may be quite effective at blocking pathways involved in certain diseases (Toogood, 2002) .
As an example of a therapeutically relevant proteinprotein interaction, we will discuss the interaction between the tumor suppressor protein p53 and the ubiquitin ligase MDM2. MDM2 binds p53, thereby exporting it from its place of action, the nucleus, and targeting it for degradation by the proteasome (Kubbutat et al., 1997) . Tumors overexpressing MDM2 effectively degrade p53, thereby preventing its anti-tumor effects. A feasible strategy to inhibit tumor growth is the inhibition of the p53-MDM2 interaction, which would lead to the stabilization of p53 and inhibition of tumor growth (reviewed in Chene, 2003) . The interaction between p53 and MDM2 represents an interesting target for inhibitor screening mainly for two reasons: (1), the interaction is Fig. (5) . Identification of peptide aptamers using the yeast two-hybrid system. (A) A bait encoding a protein of interest fused to a DBD is cotransformed with a library of small random peptides displayed in the loop region of an appropriate scaffold protein, such as thioredoxin, which in turn is fused to the AD. (B) The interaction of a displayed peptide with the bait results in the formation of a hybrid transcription factor and the consequent activation of reporter genes, leading to cell growth on selective medium. therapeutically relevant, i.e. disruption of MDM2 binding to p53 has an immediate beneficial effect by increasing p53 levels in the cell; (2), a crystal structure of the p53-MDM2 complex shows that the interaction occurs via binding of an alpha-helical stretch of p53 in a narrow groove on the surface of MDM2 (Kussie et al., 1996) . Thus, the binding site of MDM2 resembles rather an active site of a kinase or a protease than a canonical protein-protein binding interface and may therefore be amenable to blocking with small molecules. Various screens have been carried out to identify small molecule inhibitors of the p53-MDM2 interaction (Duncan et al., 2001; Stoll et al., 2001; Vassilev et al., 2004; Zhao et al., 2002) . Although none of these inhibitors are potent enough to qualify as a drug, they show that the basic concept of inhibiting a protein-protein interaction by a small molecule is valid and may be applied to any disease pathway where blocking an interaction is thought to have a therapeutic benefit.
As a genetic selection assay for protein-protein interactions, the yeast two-hybrid system can also be used to screen for inhibitors, with relatively minor modifications. When searching for an inhibitor of a protein-protein interaction, selection has to be reversed: addition of the inhibitor would lead to a failure to express the reporter gene and, consequently, a failure of the cell to grow on selective medium. Clearly, such a selection would not be particularly useful in the context of a screen where several hundred thousand compounds have to be assayed. Instead, so-called "negative selection markers" are employed. When expressed, these reporter genes act to convert a compound present in the selection plates into a metabolite that is toxic to the cells. The most commonly used reporter is the URA3 gene which converts the compound 5-fluoroorotic acid (5FOA) into a toxic metabolite, resulting in growth arrest and cell death (Vidal et al., 1996) . Screening yeast cells that express two interacting protein partners against a collection of small molecules on plates containing 5FOA will identify the compounds that block the protein-protein interaction, thereby preventing expression of the URA3 reporter (Fig. 6) . This "reverse yeast two-hybrid" system has been adapted to a high-throughput format and has been used to demonstrate the disruption of activin receptor R1 binding to the immuophilin FKBP12 by the small molecule FK506 (Huang and Schreiber, 1997) .
In another example, the yeast two-hybrid system has been used to isolate small molecule inhibitors that interrupt the association of N-type calcium channel subunits (Young et al., 1998) . A plate assay was used to selectively isolate compounds that blocked the interaction between the N-type calcium channel β3 subunit and the I/II intracellular loop of the α 1B subunit. Out of over 156, 000 compounds tested, 10 compounds specifically blocked the β 3 subunit. Using a range of cellular assays, the authors then showed that the isolated compounds indeed alter channel conductance by selectively blocking the interaction between the α1B and β 3 subunit and not by non-specifically blocking the channel pore.
An alternative approach to screening using the yeast twohybrid system has been described by Serebriiskii and coworkers (2002) where two colorimetric reporters are used to measure the disruption of a protein-protein interaction by small molecules. Application of this selection system to drug discovery has been demonstrated by isolating small molecule inhibitors of the interaction between Ras and Raf-1. Again, the compounds isolated in the yeast two-hybrid screen were shown to be active in a cellular setting: application of the compounds to HT1080 cells caused reversion of rastransformed phenotypes including morphology, in vitro invasiveness, and anchorage-independent growth (KatoStankiewicz et al., 2002) .
Despite these encouraging reports, several obstacles remain for efficient high-throughput screening of inhibitors of protein-protein interactions in yeast. A limitation to screening for small molecule inhibitors in yeast is its ability to rapidly remove foreign compounds by means of efflux transporters encoded by the yeast PDR5 (Pleiotropic Drug Resistance), SNQ2 and YOR1 genes (Kato-Stankiewicz et al., 2002) . This problem may be overcome by using yeast strains that are deficient for the transcription factors pdr1 and pdr3 which control expression of a wide range of drug efflux pumps (Kato-Stankiewicz et al., 2002; Kaur and Bachhawat, 1999; Kolaczkowski et al., 1998) . A more serious problem is that the majority of today's drug targets are integral membrane proteins, such as ion pumps, transporters and cell surface receptors. Due to their localization in the plasma membrane, these proteins are fundamentally unsuited to yeast two-hybrid screening, which requires the interacting proteins to be located in the nucleus. Novel genetic systems, such as the split-ubiquitin membrane-based yeast two-hybrid systems (Stagljar et al., 1998; Thaminy et al., 2003; Wittke et al., 1999) , the reverse ras system (Hubsman et al., 2001) or a recently described genetic selection system modeled on the unfolded protein response (Urech et al., 2003) may help to overcome these problems.
In summary, screening for small molecules that inhibit a protein-protein interaction in yeast is a promising route, provided that the genetic systems used allow sampling of all proteins regardless of their localization within the cell, and that reporter readouts compatible with established highthroughput screening platforms are used.
PROTEIN MICROARRAYS AND THEIR APPLI-CATION IN DRUG DISCOVERY
In recent years DNA microarray technology has emerged as one of the most promising tools for large-scale high throughput biology (Howbrook et al., 2003; Mantripragada et al., 2004) . Since mRNA transcript levels do not necessarily correlate to protein levels, the focus has begun to move from DNA microarrays to protein microarrays to study the ultimate effectors in the cell. Current technologies for global analysis of the proteome include two-dimensional gel electrophoresis, chromatography and mass spectrometry . However, these methods require large amounts of sample and are often not amenable to highthroughput studies. Recently, however, several biochemical approaches using standard affinity tagging methods combined with mass spectrometric (MS) analysis has proven sufficiently robust to apply it to yeast and human protein complexes on a large scale (Bouwmeester et al., 2004; Gavin et al., 2002; Ho et al., 2002) . Although this method is extremely powerful, it remains difficult to distinguish specific from nonspecific interactions and to detect quantitative changes in protein complex abundance and composition. Protein microarray (also called protein chip) technology is promising to overcome these bottlenecks.
Principally, protein microarrays consist of proteins, peptides or antibodies immobilised on a surface, which can be probed by a ligand to study protein-protein, protein-lipid, protein-nucleic acid or protein-small molecule interactions (Fig. 7) . Binding is commonly detected by fluorescence, either by directly labelling the probe, or by using a fluorescent antibody. Alternative detection methods include ELISA, mass spectrometry, atomic force microscopy or radioactivity . MacBeath and Schreiber (2000) were among the first to show the potential of protein chips for drug target discovery. They spotted biotin, a monoclonal antibody and a synthetic amide on a glass slide in the microarray format and demonstrated a previously known interaction with a small molecule. In 2001, the group of Michael Snyder developed the first proteome chip. They expressed 80% of all yeast fulllength open reading frames (ORFs) as fusions to tandem GST and polyhistidine affinity tags, purified them and then robotically arrayed the purified proteins onto microscopic glass slides. Such protein arrays were screened using Calmodulin as bait, and 6 known and 33 potentially new interaction partners were identified. To further demonstrate the wide applicability of protein microarray screening, the Fig. (6) . The reverse yeast two-hybrid system. (A) Co-expression of an interacting DBD-X bait and an AD-Y prey activates expression of the URA3 gene, which converts 5FOA into a metabolite that is toxic to the cell. Consequently, yeast co-expressing the interaction partners will be unable to grow on 5FOA containing medium. (B) Addition of a small molecule that disrupts the interaction between DBD-X and AD-Y abolishes the hybrid transcription factor and silences expression of URA3. Yeast which has been treated with this small molecule is therefore able to grow on 5FOA containing plates.
authors also used liposomes to screen for proteins that interact with the lipid phosphoinositide (Zhu et al., 2001) . In addition, the group used the yeast proteome chip to analyze 11 monoclonal and polyclonal antibodies for specificity. They found that the antibodies crossreacted with unpredicted proteins to varying degrees (Michaud et al., 2003 ).
An interesting application of the protein microarray technology to G-protein coupled receptors (GPCRs) has recently been described (Fang et al., 2002) . GPCRs constitute one of the most important families of membrane receptors through which cells communicate with each other and organisms adapt to changes in the internal and external milieus (Pierce et al., 2002) . Their medical importance is reflected by the fact that they are targeted by ~30% of all medicines making them extremely valuable targets for the pharmaceutical industry. Fang and coworkers (2002) have used GPCR-based protein chips to demonstrate selectivity and dose dependence of compound binding to different GPCR receptors. Arraying a dopamine, an adrenergic and the neurotensin receptor, they showed binding specificity of neurotensin to the neurotensin receptor. Furthermore, they probed adrenergic receptors with selective antagonists and demonstrated that GPCR microarrays can be used to determine compound specificity within a receptor subtype.
Currently, major applications of protein microarrays are the study of protein-protein interactions and protein-small molecule interactions as well as antibody specificity profiling, and immune profiling on a proteome wide scale . A major application of protein chips in drug discovery will be to study the effect of a putative drug on the cell's protein expression profile. The alteration in protein expression levels upon drug treatment will provide insight into the mechanism of action. Furthermore, protein chips have the potential to be applied in drug development to screen for drug toxicity and to study its mechanism. Protein extracts from the target organ can be analysed for a change in protein expression after overdosing the drug. New insights into mechanistic toxicity can then be used for drug improvement or new drug design.
The yeast proteome microarray technology represents a highly interesting platform for the drug development process for target discovery, validation, selection, differentiation and metabolic profiling with yeast as a model organism. Improvements in chip production have increased the complexity of protein microarrays, allowing simultaneous high-throughput, multi-parametric analysis of complex protein mixtures consisting of thousands of proteins on a single chip. Development of commercially available protein chips is still in its Fig. (7) . Protein microarrays. A typical protein microarray consists of an array of proteins, peptides or antibodies. It can be probed with proteins, lipids, small molecules and nucleic acid. Capture of the analyte is detected by fluorescence, radiation, mass spectrometry or atomic force microscopy (AFM).
beginning and struggles with issues such as protein complexity on the chip, large scale production and long term storage. Nevertheless, we can expect protein chips to play a major role in drug development in the near future.
CONCLUSION AND FUTURE DIRECTIONS
A new era in biological research has arrived with the application of various functional genomic and proteomic technologies, and the bakers yeast S. cerevisiae has played crucial roles in their development (Snyder and Kumar, 2002) . Since the major signaling pathways and cellular processes are conserved between yeast and mammalian cells, and since yeast is amenable to high-throughput studies, yeast also represents an interesting model organism for drug discovery. The last couple of years of research have seen dozens of successful examples which use yeast for drug discovery purposes (Bach et al., 2003; Bedalov et al., 2001; Young et al., 1998) . Although whole cell screens should ideally be performed within human cells thus providing the most physiological model system, the recent yeast-based functional genomic and proteomic technologies provide an inexpensive, robust and alternative approach for the identification of novel drug targets and chemicals which modulate their biological functions. One current drawback is the fact that these technologies are still at an early "proof of principle" stage for drug discovery. The real proof for these technologies will be for them to identify a chemical compound which can be used as a valuable drug in humans. Within the next decade, we will no doubt see many new examples of successful applications of drug screenings in yeast and their likely appearance in the drug market.
